Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Germany's Vaccine Commission Recommends Novavax's COVID-19 Vaccine For Adults: Reuters

Germany's expert panel on vaccine use has recommended Novavax Inc's (NASDAQ:NVAX) protein-based COVID-19 vaccine for primary immunization for people over 18 years.

  • The advisory group known as STIKO said a booster shot should still be given with an mRNA vaccine, reported Reuters.
  • mRNA technology is behind the two most commonly used COVID-19 vaccines from - Pfizer Inc (NYSE:PFE) / BioNTech SE (NASDAQ:BNTX) and Moderna Inc (NASDAQ:MRNA).
  • Novavax's COVID-19 vaccine NVX-CoV2373 is a protein-based vaccine engineered from the genetic sequence of the first strain of SARS-CoV-2. It is formulated with an adjuvant to enhance the immune response and stimulate high neutralizing antibodies.
  • Germany expects to receive 3.8 million doses of Novavax's Nuvaxovid vaccine by March 20 and a total of 34 million this year.
  • STIKO also updated its general recommendation for booster shots and now advises at-risk groups, including those aged 70 and over. Health workers to get a second booster, or a fourth shot overall, against COVID-19 with an mRNA vaccine.
  • Novavax also received provisional approval from New Zealand's medicines regulator for its COVID-19 vaccine, Nuvaxovid, for individuals 18 years of age and older.
  • Novavax and the New Zealand Government previously announced an advance purchase agreement for 10.7 million Novavax's COVID-19 vaccine doses.
  • Yesterday, Britain's regulatory agency gave conditional approval to Novavax's COVID-19 vaccine.
  • Price Action: NVAX shares are trading 3.59% higher at $91.67 during the premarket session on the last check Friday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.